Clinical Trial · NCT02989623

Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA

Overview

This pilot phase I trial studies how well copper Cu 64 TP3805 positron emission tomography (PET) works in detecting prostate cancer in patients with persistently elevated prostate specific antigen (PSA). The copper Cu 64 TP3805 PET scan uses copper Cu 64 TP3805, a compound made of a radioactive agent attached to a molecule that looks like a hormone that binds to cancer cells to detect prostate cancer during PET scans. Copper Cu 64 TP3805 PET may be able to see tumors at an earlier stage than the standard of care.

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Phase

N/A

Contacts

Madhukar Thakur, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02989623

Drug / Compound

TP3805

Isotope(s):

Target(s):

VPAC1

Ligand Class: Peptides

Chelator: N2S2

Eligibility

Inclusion

Persistently elevated PSA
Scheduled for magnetic resonance imaging (MRI) fusion/transrectal ultrasound (TRUS) biopsy, followed by histology

Exclusion

Exclusion criteria not yet provided.